Connect Biopharma Holdings Ltd

CNTBNASDAQ · USD
0.64USD-0.04 (-5.05%)
132

Connect Biopharma Holdings Ltd (CNTB) Option Chain

Read more

Tracking the CNTB option chain helps you see every strike and expiry on Connect Biopharma Holdings Ltd in one view, so you can quickly identify contracts that fit your thesis and your risk. It lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of CNTB options activity at a glance. Use our scanner to monitor the CNTB option chain in real time and filter for the trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For CNTB stock options, the chain shows call and put data side by side, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading it well means looking beyond the last price. Implied volatility by strike, volume to open interest ratios, and bid ask spreads all show where CNTB options are being actively traded, and where they are not.

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation.

2026-11-20
5 strikes
Default
CALLsPUTs
Prob. OTM %Open InterestVolumeExtrinsic ValueIntrinsic ValueBidAskStrikeMoneyness %BidAskIntrinsic ValueExtrinsic ValueVolumeOpen InterestProb. OTM %
100.003000.860.14—1.000.50-26.47—1.000.001.00000.00
100.008301.000.00—1.001.00+47.060.051.050.360.190100.00
100.00001.000.00—1.001.50+120.590.351.350.86-0.01000.00
100.00000.050.00—0.052.00+194.120.851.851.36-0.01000.00
100.005100.050.00—0.052.50+267.651.352.351.86-0.01000.00

As of Nov 13, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank94.84% High
  • Market cap (M$)43
  • 52 weeks high-82.20%
  • 52 weeks low3.03%
  • Analyst recommendationStrong Buy
    1.00
  • Target price$6.03
    837.79% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-08-12
  • P/E—
  • Future P/E—
  • EPS (ttm)-1.20
  • EPS growth next 5 years7.88%

As of Nov 13, 2026